<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051502</url>
  </required_header>
  <id_info>
    <org_study_id>19-271</org_study_id>
    <nct_id>NCT04051502</nct_id>
  </id_info>
  <brief_title>ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study</brief_title>
  <official_title>ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be&#xD;
      identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number and location of ovarian sentinel lymph nodes visually identified after injection of ICG dye via one of three tested methods.</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate for dye uptake in the regional lymphatic channels, and in the pelvic and para-aortic nodes using infrared imaging.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Adnexal Mass</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>First group of 10 participants enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Second group of 10 participants enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Third group of 10 participants enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Fourth group of 10 participants enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Method 1: Indocyanine green dye</intervention_name>
    <description>Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>ICG dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Method 2: Indocyanine green dye</intervention_name>
    <description>1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located&#xD;
Dorsal side of the IP ligament&#xD;
Ventral side of the IP ligament&#xD;
Dorsal side of the utero-ovarian ligament&#xD;
Ventral side of the utero-ovarian ligament</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>ICG dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Method 3: Indocyanine green dye</intervention_name>
    <description>Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>ICG dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Method 3: Indocyanine green dye</intervention_name>
    <description>Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from the Gynecology Service, Department of Surgery. All women&#xD;
        undergoing surgery for an adnexal mass, with or without a hysterectomy, without clear&#xD;
        preoperative suspicion for advanced stage ovarian disease will be screened for&#xD;
        participation in this study. No selectivity will be exercised by the investigators as to&#xD;
        minimize bias. The specific type of surgery, as well as its timing, will be determined by&#xD;
        the treating gynecologic surgeon&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women undergoing surgery with the Gynecology Service at MSK.&#xD;
&#xD;
          -  Women undergoing surgery for an adnexal mass without pre-operative suspicion of high&#xD;
             stage disease, with or without a hysterectomy&#xD;
&#xD;
             Â°For this protocol, &quot;suspected high stage disease&quot; will be defined as any patient with&#xD;
             radiologic or clinical evidence of ovarian cancer which has spread outside of the&#xD;
             ovary. Thus, only patients with an adnexal mass, or bilateral adnexal masses, are&#xD;
             eligible.&#xD;
&#xD;
          -  Women in whom MIS surgery is converted to a laparotomy will not be excluded as both&#xD;
             surgical approaches, MIS and open, will be utilized.&#xD;
&#xD;
          -  Women &gt;/= 18 years of age&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Albumin levels within normal range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current non-GYN primary malignancy&#xD;
&#xD;
          -  Prior or current history of uterine, cervical, peritoneal, or vulvovaginal malignancy&#xD;
&#xD;
          -  Ongoing anticancer therapy&#xD;
&#xD;
          -  Prior bilateral oophorectomy&#xD;
&#xD;
          -  Known severe anaphylactic iodide allergy&#xD;
&#xD;
          -  Known history of cirrhosis or other chronic liver disease, or women with hepatic&#xD;
             dysfunction.&#xD;
&#xD;
          -  Elevated transaminases (ALT, AST) and/or Alk Phos will be evaluated by the treating&#xD;
             physician on a case by case basis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginger Gardner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ginger Gardner, MD</last_name>
    <phone>212-639-2375</phone>
    <email>gardnerg@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dennis Chi, MD</last_name>
    <phone>212-639-5016</phone>
    <email>chid@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge (Consent only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent only )</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent only)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent only)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Gardner, MD</last_name>
      <phone>212-639-2375</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Adnexal Mass</keyword>
  <keyword>Ovarian Sentinal Lymph Nodes</keyword>
  <keyword>19-271</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>Sentinal Lymph Nodes</keyword>
  <keyword>indocyanine green dye</keyword>
  <keyword>ICG Dye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

